- Advertisement -First vaccine for chikungunya virus, an ’emerging global health threat,’ gets FDA approvalIxchiq, the first chikungunya vaccine, has been approved by the FDAThe vaccine is made by Valneva and is approved for adults aged 18 and older at risk of exposure to the virusChikungunya is transmitted through mosquito bites and has been described as an “emerging global health threat” by the FDAThe vaccine’s safety and efficacy were tested in clinical trials before approvalFirst vaccine for chikungunya virus, an ’emerging global health threat,’ gets FDA approvalThe U.S. Food and Drug Administration has approved Ixchiq, the first chikungunya vaccine, made by Valneva, for adults aged 18 and older who are at risk of exposure to the virus. Chikungunya is an “emerging global health threat” transmitted through mosquito bites, leading to severe disease and prolonged health problems. Significant ThemesThe FDA’s Approval- Advertisement -The FDA described chikungunya as an “emerging global health threat,” with at least five million cases reported over the past 15 years. Vaccine Safety and EfficacyBefore the FDA’s approval, the vaccine’s safety was tested in clinical trials that included 3,500 adults. - Advertisement -Efficacy StudyIn a separate study, the vaccine’s efficacy was measured based on the immune response data of 266 adult participants.

Source: Mint November 12, 2023 11:49 UTC